2015 American Transplant Congress
Differences in Reactivity of HLA-Specific Antibodies May Be Explained By Differences in Their Affinities for Selected Epitopes on HLA Proteins
Affinity of IgG immunoglobulins for antigen varies and matures within the evolution of immune responses. Affinity is likely to be different for different epitope-antibody interactions…2015 American Transplant Congress
Renal Outcomes of Cross Match Positive Simultaneous Liver Kidney (SLK) Transplant Recipients Compared to Cross Match Positive Kidney Allograft Recipients
The protective role of liver in cross-match(XM) positive SLK recipients and its impact on the incidence of renal antibody mediated rejection (AMR) is unclear.A retrospective…2015 American Transplant Congress
Incidence and Clinical Severity of Hypogammaglobulinemia (Hypo-IgG) in Highly-HLA Sensitized Patients (HS) Undergoing Desensitization (DES)
Introduction: Desensitization therapies (DES) have dramatically improved rates of transplantation among HS patients. However, antibody-reduction and B-cell/plasma cell directed therapies could have implications for humoral…2015 American Transplant Congress
Post-Kidney Transplant Infections in Desensitized Patients Receiving Thymoglobulin or Daclizumab Induction: Results of a Randomized Clinical Trial
Live donor kidney transplant recipients requiring desensitization for donor-specific antibody, who were enrolled in a single-center randomized trial of thymoglobulin vs. daclizumab induction, were evaluated…2015 American Transplant Congress
Infectious Complications in ABO Incompatible Kidney Transplantation Recipient According to the Rituximab Dose
BackgroundDesensitization with rituximab and intravenous immunoglobulin improves ABO incompatible (ABOi) kidney transplantation (KT) outcomes. However, infections have been noted in association with rituximab administration. In…2015 American Transplant Congress
Extended Analysis of Tocilizumab (anti-IL-6R) + Intravenous Immunoglobulin (IVIG) as Desensitization (DES) Agents for Reduction of Donor Specific Antibodies (DSA) in Patients Resistant to DES With IVIG + Rituximab
Kidney Transplant, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: IVIG+rituximab is an acceptable approach for DES with good outcomes. Despite this, ∼30% of patients fail DES, thus other approaches are needed. Options include…2015 American Transplant Congress
Mesenchymal Stem Cells (MSCs) Transfusion for Desensitization of Positive Lymphocyte Cross Match (LCM) or Panel Reactive Antibodies (PRA) Before Kidney Transplantation – Outcome of 16 Cases
Immunomodulatory function of MSCs may correct positive PRA or LCM in highly-sensitized patients. We evaluate donor specific or 3rd party MSCs transfusion in 16 patients…2015 American Transplant Congress
Quantifying the Survival Benefit of HLA-Incompatible Kidney Transplantation: A Multi-Center Study
Surgery, Hopkins, Baltimore, MD.
A single center study has demonstrated a two-fold survival benefit of incompatible live donor kidney transplant (ILDKT) compared to remaining on dialysis. We sought to…2015 American Transplant Congress
Desensitization Protocol Including Concomitant Bortezomib and Rituximab Did Not Reduce Calculated PRA Nor Mean MFI Values Among Waitlisted Patients for Deceased Donor Kidney Transplantation
Highly sensitized (HS) patients (pts) seldom have chance to receive deceased donor kidney transplant (DDKT). A desensitization (DES) program including bortezomib was employed to facilitate…2015 American Transplant Congress
Long-Term Analysis of a Placebo-Controlled Trial of C1-INH for Prevention of Antibody-Mediated Rejection
Kidney Transplant, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: Desensitization (DES) strategies focus primarily on antibody reduction using IVIG, rituximab ± PLEX to prevent DSA-induced antibody-mediated rejection (ABMR) and rebound B-cell activity. Recently,…
American Transplant Congress abstracts